Cancer Biology and Therapeutics is an intricate field at the forefront of medical research, dedicated to unravelling the complexities of cancer at the molecular, cellular, and genetic levels. The discipline involves a profound exploration of the mechanisms driving cancer initiation, progression, and metastasis. Researchers in Cancer Biology aim to understand the intricate interplay between genetic mutations, signalling pathways, and the tumour microenvironment that contribute to the development of various cancer types.
The ultimate goal of Cancer Biology is to translate these insights into innovative therapeutic strategies. Cancer Therapeutics involves the development of targeted therapies, immunotherapies, and precision medicine approaches tailored to individual patients. With advancements in genomics and molecular profiling, there is a growing emphasis on identifying specific molecular targets within cancer cells, paving the way for more effective and less toxic treatments. In essence, Cancer Biology and Therapeutics form a dynamic and evolving field, where cutting-edge research meets the urgent need for more precise, personalized, and impactful cancer treatments.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia